Navigation Links
Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results

WALTHAM, Mass., Nov. 7 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market, today announced results for its third quarter ended September 30, 2007.

The Company recorded revenue of $2.6 million for the third quarter, compared to revenue of $1.3 million for third quarter ended September 30, 2006, a 92% increase. Net loss for the quarter was $1.1 million, or $(0.04) per basic and diluted share compared to a net loss of $1.8 million, or $(0.07) per basic and diluted share for the same quarter last year.

The increase in revenue for the third quarter was attributable to the Company's Consumer Products segment which sells branded nutritional supplemental products to mass retail outlets. Interleukin reported $158,000 in revenue from its Genetic Testing segment, $1.8 million in revenue from its Consumer Products segment and $609,000 in revenue from its Research segment.

"During the quarter we refined our focus to better leverage our science and further establish Interleukin's leadership position in genetic testing and the personal wellness field", said Thomas Curran, interim Chief Executive Officer. "We have prioritized new product development programs in areas of significant opportunity such as gastric cancer and obesity. We continue to focus our efforts on our strategic relationship with Alticor to ensure strong marketing efforts and a positive consumer experience. As we look forward to the rollout of additional products in coming years we continue to explore new delivery channels and other potential strategic partners worldwide."

Quarter Update

-- In collaboration with Dr. Steven Abramson, Director of the Division of

Rheumatology at the Hospital for Joint Diseases of New York University

Medical Center, Interleukin has initiated a study on the genetics of


-- An Interleukin Genetics study published in Nutrition reported that a

botanical supplement that included rose hips, a blueberry and

blackberry mixture and a grape vine extract, reduced inflammation more

effectively in individuals with genetic variations that are associated

with over-expression of inflammation and risk for early heart attacks.

-- The Company continues to expand its scientific advisory board, having

recently announced the addition of Dr. Emad E-Omar, a gastric cancer

expert and Drs. James Meigs and John Foreyt, both obesity/diabetes

management experts. These three advisors will help to guide

Interleukin's development programs in key growth areas related to

obesity and weight management, and gastric cancer.

"We are particularly excited about opportunities for Interleukin regarding gastric cancer, which is the second most common cause of cancer deaths worldwide", added Ken Kornman, President and Chief Scientific Officer. "Utilizing our research and proprietary genetic technology in the field of inflammation, we expect to develop tests that will contribute towards improving the prevention and medical management of gastric cancer. We plan to conduct studies in Asia in 2008 and anticipate having a product in the marketplace in the second half of 2009. We are also making good advances on the development of our weight loss test and expect to begin studies in medical weight loss clinics in the U.S. in 2008."

Research and development expenses were $786,000 compared to $721,000 for the third quarter of 2006. This increase primarily reflects the timing of third party costs related to ongoing research projects.

There were no significant changes in selling, general and administrative expenses for the period. Interleukin reported selling, general and administrative expenses $1.2 million for the quarter ended September 2007, compared to $1.2 million for the same period last year.

Balance Sheet

Interleukin reported cash and cash equivalents of $8.0 million as of September 30, 2007, compared to $10.1 million at December 31, 2006. Under its credit facility the Company had access to $14.3 million on September 30, 2007.

ILI Earnings Conference Call

To access the live call on November 7, 2007 at 4:30 PM EST, dial (800) 366-3964 (domestic) or (303) 205-0055 (international). The call will also be available live via webcast at

Replay access of the teleconference will be available for two weeks following the call by calling (800) 405-2236 (domestic) or (303) 590-3000 (international). The passcode for the replay is 11101550. The webcast will be archived following the call at

About Interleukin

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, our ability to make progress in advancing our core technologies, our ability to identify suitable commercial partners and enter into favorable agreements with them, and our expectations regarding future revenues from our nutritional supplement products. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, our ability to integrate acquired businesses, our ability to maintain relationships with our important customers, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2006, as amended, filed with the Securities and Exchange Commission, our quarterly reports on Form 10- Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.



Balance Sheet Data:

September 30, December 31,

2007 2006

(Unaudited) (Audited)

Cash and cash equivalents $8,058,276 $10,082,919

Total current assets 10,468,352 12,991,113

Total assets $18,795,836 $22,630,285

Total current liabilities $6,927,948 $7,388,353

Total liabilities 9,157,742 8,844,354

Total shareholders' equity 9,638,094 13,785,931

Total liabilities and shareholders'

equity $18,795,836 $22,630,285

Statement of

Operations Data Three Months Ended Nine Months Ended

(Unaudited): September 30, September 30,

2007 2006 2007 2006


Genetic testing

service revenue $157,645 $654,482 $648,910 $2,219,145

Net consumer

products sales 1,792,688 674,725 5,173,555 674,725

Contract research

revenue 609,234 - 1,558,206 -

Other 1,718 5,724 8,360 17,975

Total revenue 2,561,285 1,334,931 7,389,031 2,911,845

Operating costs and


Cost of genetic

testing services 211,953 331,836 721,090 937,770

Cost of consumer

products sold 995,769 675,101 2,882,072 675,101

Research and

development 785,942 721,731 2,246,340 2,382,390

Selling, general and

administrative 1,163,531 1,196,263 4,821,032 2,702,517

Amortization of

intangibles 413,209 145,322 1,236,074 193,830

Total operating

costs and

expenses 3,570,404 3,070,253 11,906,608 6,891,608

Loss from operations (1,009,119) (1,735,322) (4,517,578) (3,979,763)

Total other income and

expense, net (68,540) (98,327) (188,680) (366,546)

Net loss before income

taxes (1,077,659) (1,833,649) (4,706,258) (4,346,309)

Provision for income

taxes (4,000) - (12,000) -

Net loss $(1,081,659) $(1,833,649) $(4,718,258) $(4,346,309)

Net loss per basic and

diluted common share $(0.04) $(0.07) $(0.17) $(0.18)

Weighted average

common shares

outstanding 27,637,303 25,702,739 27,576,940 24,653,698

SOURCE Interleukin Genetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Announces Management and Board Appointments
2. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology:
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):